HOLLINGS RENTON - 15 Jul 2024 Form 4 Insider Report for ANAPTYSBIO, INC (ANAB)

Role
Director
Signature
/s/ Eric Loumeau, Attorney-in-Fact
Issuer symbol
ANAB
Transactions as of
15 Jul 2024
Net transactions value
-$237,122
Form type
4
Filing time
17 Jul 2024, 16:45:35 UTC
Previous filing
18 Jun 2024
Next filing
03 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANAB Common Stock Options Exercise $69,300 +10,000 +513% $6.93 11,950 15 Jul 2024 Direct
transaction ANAB Common Stock Sale $216,668 -7,103 -59% $30.50 4,847 15 Jul 2024 Direct F1, F2
transaction ANAB Common Stock Sale $89,754 -2,897 -60% $30.98 1,950 15 Jul 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANAB Common Stock Options Exercise $0 -10,000 -24% $0.000000 30,925 15 Jul 2024 Common Stock 10,000 $6.93 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024. Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options before their expiration.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.92 to $31.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option grant was issued on July 6, 2015, is fully vested and exercisable until its expiration date of July 5, 2025.